loading...| Preferred Name | chronic myelogenous leukemia, BCR-ABL1 positive | |
| Synonyms |
leukemia, chronic myeloid, atypical leukemia, chronic myelogenous leukemia, chronic myeloid chronic granulocytic leukemia chronic myeloid leukemia chronic myelogenous leukemia, BCR-ABL1 Positive BCR-ABL Positive chronic myelogenous leukemia chronic myelocytic leukemia chronic myelogenous leukemias leukemia, chronic myeloid, Philadelphia chromosome positive, somatic CML - chronic myelogenous leukemia leukemia, Philadelphia chromosome-positive, resistant to imatinib, Somatic mutation CML hematopoeitic - chronic myelocytic leukemia (CML) myeloid leukemia, chronic chronic myelogenous leukemia (CML) chronic myelogenous leukemia |
|
| Definitions |
A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival. |
|
| ID |
http://purl.obolibrary.org/obo/MONDO_0011996 |
|
| altLabel |
leukemia, chronic myeloid, atypical leukemia, chronic myelogenous leukemia, chronic myeloid chronic granulocytic leukemia chronic myeloid leukemia chronic myelogenous leukemia, BCR-ABL1 Positive BCR-ABL Positive chronic myelogenous leukemia chronic myelocytic leukemia chronic myelogenous leukemias leukemia, chronic myeloid, Philadelphia chromosome positive, somatic CML - chronic myelogenous leukemia leukemia, Philadelphia chromosome-positive, resistant to imatinib, Somatic mutation CML hematopoeitic - chronic myelocytic leukemia (CML) myeloid leukemia, chronic chronic myelogenous leukemia (CML) chronic myelogenous leukemia |
|
| definition |
A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival. |
|
| has_exact_synonym |
chronic granulocytic leukemia chronic myeloid leukemia chronic myelogenous leukemia, BCR-ABL1 Positive BCR-ABL Positive chronic myelogenous leukemia chronic myelocytic leukemia chronic myelogenous leukemias leukemia, chronic myeloid, Philadelphia chromosome positive, somatic CML - chronic myelogenous leukemia leukemia, Philadelphia chromosome-positive, resistant to imatinib, Somatic mutation CML hematopoeitic - chronic myelocytic leukemia (CML) myeloid leukemia, chronic chronic myelogenous leukemia (CML) chronic myelogenous leukemia |
|
| has_related_synonym |
leukemia, chronic myeloid, atypical leukemia, chronic myelogenous leukemia, chronic myeloid |
|
| IAO_0000233 | ||
| label |
chronic myelogenous leukemia, BCR-ABL1 positive |
|
| prefixIRI |
MONDO:0011996 |
|
| prefLabel |
chronic myelogenous leukemia, BCR-ABL1 positive |
|
| textual definition |
A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival. |
|
| subClassOf |